Skip to content
value.today

Angle plc: peers

Change the peers

Angle plc beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Angle plc, EKF Diagnostics Holdings plc, BioPorto A/S, Renalytix plc, Gentian Diagnostics AS, Burning Rock Biotech Limited: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Angle plc, OneMedNet Corp, EKF Diagnostics Holdings plc, BioPorto A/S, Renalytix plc, Gentian Diagnostics AS, Insight Molecular Diagnostics Inc., Burning Rock Biotech Limited side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureAngle plcbase
AGL.L · 🇬🇧 GB
Percentile in Healthcare
Percentile in UK
OneMedNet Corp
ONMD · 🇬🇧 GB
Percentile in Healthcare
Percentile in UK
EKF Diagnostics Holdings plc
EKF.L · 🇬🇧 GB
Percentile in Healthcare
Percentile in UK
BioPorto A/S
BIOPOR.CO · 🇩🇰 DK
Percentile in Healthcare
Percentile in Denmark
Renalytix plc
RNLXY · 🇬🇧 GB
Percentile in Healthcare
Percentile in UK
Gentian Diagnostics AS
6FK.F · 🇳🇴 NO
Percentile in Healthcare
Percentile in Norway
Insight Molecular Diagnostics Inc.
IMDX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Burning Rock Biotech Limited
BNR · 🇨🇳 CN
Percentile in Healthcare
Percentile in China
Group median
Size
Market cap (Better neither way: ranked highest first)$104 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one4th of 8$237 MOct 14, 2026 · Market data1st of 8$182 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one2nd of 8$118 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8$21 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one8th of 8$71 Mlast known, Jul 30, 2023 · Market dataLast known value: no current one7th of 8$98 MOct 27, 2026 · Market data5th of 8$93 MAug 1, 2026 · Market data6th of 8$101 M8 ranked
Revenue (Better neither way: ranked highest first)——$1 MFY2025 · SEC5th of 5————$2 MFY2024 · SEC4th of 5$17 MFY2025 · ESEF2nd of 5$4 MFY2025 · SEC3rd of 5$77 MFY2025 · SEC1st of 5$4 M5 ranked
Net income (Higher is better)——$-3 MFY2025 · SEC2nd of 5————$-33 MFY2024 · SEC4th of 5$1 MFY2025 · ESEF1st of 5$-50 MFY2025 · SEC5th of 5$-8 MFY2025 · SEC3rd of 5$-8 M5 ranked
Employees (Better neither way: ranked highest first)——————15as reported · Profile2nd of 2——————753As on 2020 · Profile1st of 23842 ranked
Growth
Revenue growth (Higher is better)————+112.5%FY2025 · SEC2nd of 592nd99th————————-32.6%FY2024 · SEC5th of 57th1st+20.0%FY2025 · ESEF3rd of 569th77th+116.0%FY2025 · SEC1st of 593rd97th+9.2%FY2025 · SEC4th of 548th55th+20.0%5 ranked
Revenue growth, 3 years a year (Higher is better)————+5.8%FY2025 · SEC3rd of 444th51st————————+15.4%FY2024 · SEC2nd of 465th80th————+61.7%FY2025 · SEC1st of 492nd97th-1.9%FY2025 · SEC4th of 422nd47th+10.6%4 ranked
Earnings per share growth (Higher is better)————————————————————-69.0%FY2025 · ESEFonly one with it4th6th————————-69.0%—
Margins and returns
Gross margin (Higher is better)————-36.8%FY2025 · SEC5th of 51st1st————————7.0%FY2024 · SEC4th of 54th5th55.6%FY2025 · ESEF3rd of 545th79th56.6%FY2025 · SEC2nd of 548th70th74.7%FY2025 · SEC1st of 574th95th55.6%5 ranked
Operating margin (Higher is better)————-711.0%FY2025 · SEC3rd of 33rd0th————————————14.4%FY2025 · ESEF1st of 381st73rd————-10.2%FY2025 · SEC2nd of 348th43rd-10.2%3 ranked
Net margin (Higher is better)————-205.9%FY2025 · SEC3rd of 315th2nd————————————7.5%FY2025 · ESEF1st of 375th68th————-10.3%FY2025 · SEC2nd of 347th41st-10.3%3 ranked
Free cash flow margin (Higher is better)————-552.2%FY2025 · SEC3rd of 46th1st————————————23.4%FY2025 · ESEF1st of 492nd88th-624.6%FY2025 · SEC4th of 44th1st-6.3%FY2025 · SEC2nd of 444th39th-279.2%4 ranked
Return on equity (Higher is better)————————————————————6.8%FY2025 · ESEF1st of 277th45th————-10.2%FY2025 · SEC2nd of 266th40th-1.7%2 ranked
Valuation
Price to sales (Better neither way: ranked highest first)————163.6×price Oct 14, 2026 · Market data1st of 296th97th————————————————24.2×price Oct 27, 2026 · Market data2nd of 285th95th1.2×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price93.9×2 ranked
Price to book (Better neither way: ranked highest first)————————————————————————————1.2×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price——
Free cash flow yield (Higher is better)————-3.2%price Oct 14, 2026 · Market data1st of 258th32nd————————————————-25.8%price Oct 27, 2026 · Market data2nd of 228th13th-5.2%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price-14.5%2 ranked
Financial strength
Interest cover (Higher is better)————-138.1×FY2025 · SEConly one with it11th3rd————————————————————————-138.1×—
Piotroski F-score (Higher is better)——5 of 9FY2025 · SEConly one with it————————————5.0 of 9—
Scorecard
Scorecard (Higher is better)——4 of 19FY2025 · Scorecard5th of 5————3 of 10FY2024 · Scorecard3rd of 53 of 5FY2025 · Scorecard1st of 55 of 17FY2025 · Scorecard4th of 54 of 13FY2025 · Scorecard2nd of 530% passed5 ranked
Valuation checks (Higher is better)——0 of 5FY2025 · Scorecard1st of 2————————0 of 5FY2025 · Scorecard1st of 2——0% passed2 ranked
Growth checks (Higher is better)——3 of 4FY2025 · Scorecard1st of 5————3 of 5FY2024 · Scorecard3rd of 51 of 2FY2025 · Scorecard4th of 54 of 6FY2025 · Scorecard2nd of 52 of 5FY2025 · Scorecard5th of 560% passed5 ranked
Profitability checks (Higher is better)——0 of 4FY2025 · Scorecard3rd of 5————0 of 2FY2024 · Scorecard3rd of 52 of 3FY2025 · Scorecard1st of 50 of 2FY2025 · Scorecard3rd of 51 of 5FY2025 · Scorecard2nd of 50% passed5 ranked
Financial health checks (Higher is better)——1 of 5FY2025 · Scorecard3rd of 4————0 of 2FY2024 · Scorecard4th of 4——1 of 3FY2025 · Scorecard1st of 41 of 3FY2025 · Scorecard1st of 427% passed4 ranked
Shareholder returns checks (Higher is better)——0 of 1FY2025 · Scorecard1st of 3————0 of 1FY2024 · Scorecard1st of 3——0 of 1FY2025 · Scorecard1st of 3——0% passed3 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)——2.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2————————56.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 2——29.7%2 ranked
Institutions holding (Better neither way: ranked highest first)——132026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 2————————442026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 2——292 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)————————————-2.5 pp2026-Q2 against 2026-Q1 · 13Fonly one with it——-2.5 pp—

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Angle plc: How market caps are worked out; OneMedNet Corp: How market caps are worked out; EKF Diagnostics Holdings plc: How market caps are worked out; BioPorto A/S: How market caps are worked out; Renalytix plc: How market caps are worked out; Gentian Diagnostics AS: How market caps are worked out; Insight Molecular Diagnostics Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Burning Rock Biotech Limited: How market caps are worked out.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Angle plc———
OneMedNet Corp-711.0%FY2025
3rd percentile in Healthcaremedian -7.7%, 674 companies
0th percentile in UKmedian 8.5%, 313 companies
EKF Diagnostics Holdings plc———
BioPorto A/S———
Renalytix plc———
Gentian Diagnostics AS14.4%FY2025
81st percentile in Healthcaremedian -7.7%, 674 companies
73rd percentile in Norwaymedian 6.0%, 95 companies
Insight Molecular Diagnostics Inc.———
Burning Rock Biotech Limited-10.2%FY2025
48th percentile in Healthcaremedian -7.7%, 674 companies
43rd percentile in Chinamedian -5.9%, 135 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$20 M$41 M$61 M$82 M2019202020212022202320242025OneMedNet Corp $1 MRenalytix plc $2 MGentian Diagnostics AS $17 MInsight Molecular Diagnostics Inc. $4 MBurning Rock Biotech Limited $77 M

Rank in the group

1st2nd3rd4th5th202020212022202320242025OneMedNet Corp: 3rd of 4 in 2022OneMedNet Corp: 4th of 4 in 2023OneMedNet Corp: 5th of 5 in 2024OneMedNet Corp: 4th of 4 in 2025OneMedNet CorpRenalytix plc: 3rd of 3 in 2021Renalytix plc: 2nd of 4 in 2022Renalytix plc: 2nd of 4 in 2023Renalytix plc: 3rd of 5 in 2024Renalytix plcGentian Diagnostics AS: 2nd of 5 in 2024Gentian Diagnostics AS: 2nd of 4 in 2025Gentian Diagnostics ASInsight Molecular Diagnostics Inc.: 2nd of 2 in 2020Insight Molecular Diagnostics Inc.: 2nd of 3 in 2021Insight Molecular Diagnostics Inc.: 4th of 4 in 2022Insight Molecular Diagnostics Inc.: 3rd of 4 in 2023Insight Molecular Diagnostics Inc.: 4th of 5 in 2024Insight Molecular Diagnostics Inc.: 3rd of 4 in 2025Insight Molecular DiagnostBurning Rock Biotech Limited: 1st of 2 in 2020Burning Rock Biotech Limited: 1st of 3 in 2021Burning Rock Biotech Limited: 1st of 4 in 2022Burning Rock Biotech Limited: 1st of 4 in 2023Burning Rock Biotech Limited: 1st of 5 in 2024Burning Rock Biotech Limited: 1st of 4 in 2025Burning Rock Biotech Limit
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearAngle plcOneMedNet CorpEKF Diagnostics Holdings plcBioPorto A/SRenalytix plcGentian Diagnostics ASInsight Molecular Diagnostics Inc.Burning Rock Biotech Limited
2025—$1 MSEC4th———$17 MESEF2nd$4 MSEC3rd$77 MSEC1st
2024—$1 MSEC5th——$2 MSEC3rd$14 MESEF2nd$2 MSEC4th$71 MSEC1st
2023—$1 MSEC4th——$3 MSEC2nd—$2 MSEC3rd$76 MSEC1st
2022—$1 MSEC3rd——$3 MSEC2nd—$1 MSEC4th$82 MSEC1st
2021————$1 MSEC3rd—$2 MSEC2nd$80 MSEC1st
2020——————$1 MSEC2nd$66 MSEC1st
2018———————$32 MSEC

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Angle plc#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • OneMedNet CorpONMD · 🇬🇧 UK
    Same industry: Diagnostics and Research · Similar size: $237 M market cap against $104 M · Same country: UK · Ratios of the last two fiscal years on file
    Market cap $237 M (Oct 14, 2026) · revenue $1 M (year to December 2025)
    95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)
    In the group
  • EKF Diagnostics Holdings plcEKF.L · 🇬🇧 UK
    Same industry: Diagnostics and Research · Similar size: $182 M market cap against $104 M · Same country: UK
    Market cap $182 M (last known, Jan 5, 2024)
    91 of 100 (industry or sector 50 + size 26 + country 15)
    In the group
  • BioPorto A/SBIOPOR.CO · 🇩🇰 Denmark
    Same industry: Diagnostics and Research · Similar size: $118 M market cap against $104 M · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $118 M (last known, Jan 5, 2024)
    91 of 100 (industry or sector 50 + size 29 + country 7 + figures on file 5)
    In the group
  • Renalytix plcRNLXY · 🇬🇧 UK
    Same industry: Diagnostics and Research · Similar size: $21 M market cap against $104 M · Same country: UK · Ratios of the last two fiscal years on file
    Market cap $21 M (last known, Jan 5, 2024) · revenue $2 M (year to June 2024)
    90 of 100 (industry or sector 50 + size 20 + country 15 + figures on file 5)
    In the group
  • Gentian Diagnostics AS6FK.F · 🇳🇴 Norway
    Same industry: Diagnostics and Research · Similar size: $71 M market cap against $104 M · Same region: Northern Europe · Ratios of the last two fiscal years on file
    Market cap $71 M (last known, Jul 30, 2023) · revenue $17 M (year to December 2025)
    90 of 100 (industry or sector 50 + size 28 + country 7 + figures on file 5)
    In the group
  • Insight Molecular Diagnostics Inc.IMDX · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $98 M market cap against $104 M · Ratios of the last two fiscal years on file
    Market cap $98 M (Oct 27, 2026) · revenue $4 M (year to December 2025)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • Burning Rock Biotech LimitedBNR · 🇨🇳 China
    Same industry: Diagnostics and Research · Similar size: $93 M market cap against $104 M · Ratios of the last two fiscal years on file
    Market cap $93 M (Aug 1, 2026) · revenue $77 M (year to December 2025)
    84 of 100 (industry or sector 50 + size 29 + figures on file 5)
    In the group
  • Yourgene Health PLCYGEN.L · 🇬🇧 UK
    Same industry: Diagnostics and Research · 5.2× smaller by market cap · Same country: UK
    Market cap $20 M (last known, Jul 30, 2023)
    84 of 100 (industry or sector 50 + size 19 + country 15)
    + Add
  • Anixa Biosciences, Inc.ANIX · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $117 M market cap against $104 M · Ratios of the last two fiscal years on file
    Market cap $117 M (Oct 29, 2026)
    84 of 100 (industry or sector 50 + size 29 + figures on file 5)
    + Add
  • Sera Prognostics, Inc.SERA · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $82 M market cap against $104 M · Ratios of the last two fiscal years on file
    Market cap $82 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    83 of 100 (industry or sector 50 + size 28 + figures on file 5)
    + Add
  • Abingdon Health PlcABDX.L · 🇬🇧 UK
    Same industry: Diagnostics and Research · 6.1× smaller by market cap · Same country: UK
    Market cap $17 M (last known, Jan 5, 2024)
    83 of 100 (industry or sector 50 + size 18 + country 15)
    + Add
  • MaxCyte, Inc.MXCT · 🇺🇸 USA
    Same industry: Diagnostics and Research · Similar size: $156 M market cap against $104 M · Ratios of the last two fiscal years on file
    Market cap $156 M (Oct 27, 2026) · revenue $33 M (year to December 2025)
    82 of 100 (industry or sector 50 + size 27 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.